Fostered by partnerships between national laboratories, academia, and the pharmaceutical industry, the field of nuclear medicines and radiopharmaceuticals has evolved over the past few decades, in parallel with advances in imaging instrumentation, radionuclide production, and radiopharmaceutical development. Nuclear reactors and particle accelerators are presently used to produce a wide array of radionuclides for diagnostic and